On September 28, 2023, MEI Pharma, Inc. issued a statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC. In the letter, the Company?s Board of Directors and management team are focused on advancing its two programs, voruciclib and ME-344, both on the cusp of reporting clinical data during the first half of 2024 that could support value creation opportunities for the benefit of all stockholders. The Company added that this is an important time for the Company, and its Board comprises directors that bring the broad and diverse experience and expertise needed to provide strong oversight and guide the business forward as the Company executes on its upcoming key milestones.

The Company stated that its Board is focused on value creation and routinely evaluates its capital allocation priorities to ensure the Company is positioning opportunities to deliver the highest returns to stockholders.